Literature DB >> 26770531

Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis.

Guoyan Qi1, Shanshan Gu1, Peng Liu1, Hongxia Yang1, Huimin Dong1.   

Abstract

Myasthenia gravis (MG) is a kind of autoimmune disease induced by transferring dysfunction of neuromuscular junction. In the present study, we developed an integrated therapy combined with traditional Chinese medicine and immuno suppressive agents to seek for an effective treatment of MG. 220 MG patients were randomly divided into two groups with different therapies. Plasma levels of acetylcholine receptors antibodies (AchRAb) and CD4(+)CD25(+) regulatory T cells (CD4(+)CD25(+)Treg) were conducted through ELISA and flow cytometry. The amount of AchRAb (8.52±0.96 vs. 5.22±0.46) and CD4(+)CD25(+)Treg (1.94±1.21 vs. 3.21±0.96) in Group A receiving integrated therapy were significantly improved compared with Group B; the clinical performance of group treated with the integrated therapy was also much better. The integrated therapy in the present study could significantly improve the condition of MG with high recovery rate and low recurrence rate, which can be employed in future clinical treatment of MG.

Entities:  

Keywords:  Myasthenia gravis; clinical performance; immunosuppressor; integrated treatment; traditional Chinese medicine

Year:  2015        PMID: 26770531      PMCID: PMC4694431     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  18 in total

1.  Detection of multiple antibodies in myasthenia gravis and its clinical significance.

Authors:  Wei-wei Wang; Hong-jun Hao; Feng Gao
Journal:  Chin Med J (Engl)       Date:  2010-09       Impact factor: 2.628

2.  Clinical treatment of myasthenia gravis with deficiency of spleen and kidney based on combination of disease with syndrome theory.

Authors:  Chao Jiang; Ping Liu; Yan Liang; Shaobo Qiu; Wenjing Bao; Jingsheng Zhang
Journal:  J Tradit Chin Med       Date:  2013-08       Impact factor: 0.848

3.  Myasthenia gravis presenting initially as acute respiratory failure.

Authors:  Seung Jun Lee; Jaehyung Hur; Tae Won Lee; Sunmi Ju; Seung Hun Lee; Ki-Jong Park; Yu Ji Cho; Yi Yeong Jeong; Jong Deog Lee; Ho Cheol Kim
Journal:  Respir Care       Date:  2014-09-02       Impact factor: 2.258

Review 4.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

Review 5.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

6.  Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis.

Authors:  P J Chien; J H Yeh; H C Chiu; Y M Hsueh; C T Chen; M C Chen; C M Shih
Journal:  Eur J Neurol       Date:  2011-05-07       Impact factor: 6.089

Review 7.  Myasthenia gravis and risks for comorbidity.

Authors:  N E Gilhus; A Nacu; J B Andersen; J F Owe
Journal:  Eur J Neurol       Date:  2014-10-30       Impact factor: 6.089

8.  CD4+ CD25(high) regulatory T cell in childhood ocular myasthenia gravis.

Authors:  Hiroshi Sakuma; Ayako Katayama; Yoshiaki Saito; Hirofumi Komaki; Eiji Nakagawa; Kenji Sugai; Masayuki Sasaki
Journal:  Brain Dev       Date:  2010-08-24       Impact factor: 1.961

Review 9.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

10.  Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey.

Authors:  F E Somnier; N Keiding; O B Paulson
Journal:  Arch Neurol       Date:  1991-07
View more
  2 in total

1.  Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials.

Authors:  Senhui Weng; Jinghao Li; Benshu Chen; Long He; Zhuotai Zhong; Linwen Huang; Shijing Zhang; Fengbin Liu; Qilong Jiang
Journal:  Trials       Date:  2022-04-27       Impact factor: 2.728

Review 2.  Efficacy and Safety of the TCM Qi-Supplementing Therapy in Patients with Myasthenia Gravis: A Systematic Review and Meta-Analysis.

Authors:  Xi-Qian Yang; Ling Liu; Wen-Yu Yang; Huan-Huan Dong; Yi-Ran Yang; Yun Li
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-03       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.